Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,131.27 -7.99 -0.25%
FTSE 100 6,587.85 3.68 0.06%
DAX 9,312.42 -5.40 -0.06%
Ticker Volume Price Price Delta
NIKKEI 14,417.53 -0.15 -0.00%
TOPIX 1,166.59 0.04 0.00%
HANG SENG 22,760.24 64.23 0.28%

Orthofix Realigns Business Units to Support Future Growth Opportunities and Announces Leadership Changes



  Orthofix Realigns Business Units to Support Future Growth Opportunities and
  Announces Leadership Changes

             Promotes Brad Niemann to President, BioStim Business

 Michael Finegan Appointed Chief Strategy Officer, and Jeff Schumm Appointed
    Chief Administrative Officer; Mark Atkinson Named Chief People Officer

Business Wire

LEWISVILLE, Texas -- June 20, 2013

Orthofix International N.V., (NASDAQ:OFIX) (the Company) today announced the
realignment of its businesses in order to better focus on operational
performance and enhance the Company’s growth potential. The Company’s
operational businesses will now include: BioStim (stimulation products), Spine
Fixation (spine implant products), Biologics (biologics products for all
applications), International Extremity Fixation, and U.S. Extremity Fixation
(orthopedic fixation systems).

In connection with the realignment, the Global Spine business will be
separated into two businesses: BioStim and Spine Fixation. Brad Niemann,
currently Orthofix’s Senior Vice President, Commercial Operations has been
promoted to President of the BioStim business, effective immediately. Mr.
Niemann has more than 15 years of experience in the medical device industry,
with a particularly strong focus and track record in expanding the utilization
of bone growth stimulation technology. Brad Mason, President and Chief
Executive Officer of Orthofix, will assume all senior management duties for
the Spine Fixation business on an interim basis. Brian McCollum, currently
President of Global Spine, will be leaving the Company on July 15, 2013.

“These organization changes are part of our overall strategic initiative to
provide more operational focus on our businesses while driving enhanced
shareholder value,” said Mr. Mason. “We are committed to developing innovative
solutions for our physician customers and the patients they serve. By managing
all bone growth stimulation products under the BioStim business, spinal
implant products under the Spine Fixation business, and biologics products
under the Biologics business, we believe we can maximize the growth potential
of these businesses. In addition, the creation of the International Extremity
Fixation and the U.S. Extremity Fixation businesses will allow us to better
focus on our key customers and key product opportunities.”

Orthofix today also announced that Mark Atkinson has been named Orthofix’s
Chief People Officer, effective immediately. Mr. Atkinson comes to Orthofix
with a strong background in organizational development and talent management.
In this newly created position, Mr. Atkinson will oversee all human resources
management, as well as be responsible for executive and employee development
and creating a corporate culture conducive to growth and success.

In addition, the Company announced the appointment of Michael Finegan as Chief
Strategy Officer and Jeff Schumm as Chief Administrative Officer. In these
newly formed roles, Mr. Finegan will oversee all strategic activities, while
Mr. Schumm will supervise all regulatory affairs, legal matters, and
government affairs.

Mr. Mason continued, “On behalf of Orthofix, I would like to welcome both Mark
and Brad to the senior management team, congratulate Mike and Jeff on their
expanded roles, and thank Brian for his many contributions and years of
service to our Company and wish him success in his future endeavors. We are
creating a strong leadership team of talented employees at Orthofix and these
promotions and appointments, together with our organization changes will
advance our objectives for the benefit of our many stakeholders.”

The Company will discuss today’s announcements, as well as its complete
Business Analysis and Key Strategic Initiatives during its second quarter 2013
earnings presentation.

About Brad Niemann:

Mr. Niemann joined Orthofix in March 2012 and has led the Company’s
reimbursement and commercial operations. With more than 15 years of experience
in the medical device industry, he has a particularly strong focus and track
record in expanding the utilization of bone growth stimulation technology.
From 2004-2012, Mr. Niemann worked in a variety of management and leadership
roles at DJO Global, Inc. including Senior Vice President, Recovery Sciences
leading their commercial efforts for the business segment.

About Mark Atkinson:

Mr. Atkinson brings to Orthofix a wealth of organizational development and
talent management experience. Most recently, Mr. Atkinson served as the
Director, Talent Management & Organizational Development for Lennox
International. Prior to that, he was a Director, Talent Management,
Organization Design and Human Resource Transformation Practices for
PricewaterhouseCoopers as well as the National Director, Human Resources for
Jenkens & Gilchrist, P.C.

About Michael Finegan:

Mr. Finegan joined Orthofix as Vice President of Corporate Development in
2006. In 2009, he assumed additional responsibilities as the President of
Biologics. Mr. Finegan came to Orthofix from the Boston Scientific
Corporation, where he held several management positions of increasing
responsibility, including Vice President of Corporate Sales. Mr. Finegan began
his career in banking with First Union (Wachovia). He graduated from Wake
Forest University with a B.A. in Economics.

About Jeff Schumm:

Mr. Schumm joined Orthofix as Assistant General Counsel in January 2007, and
was promoted to Senior Vice President, General Counsel and Corporate Secretary
in October 2010. From 2004 to 2006, Mr. Schumm served as Vice President and
General Counsel for Regeneration Technologies, Inc. Earlier in his career, he
served as an Assistant Attorney General for the State of Florida, as an
associate at Holland & Knight LLP and as a Staff Attorney at the Supreme Court
of Florida. Mr. Schumm received his Bachelors of Science in Electrical
Engineering and Masters in Business Administration from Lehigh University, and
he is a magna cum laude graduate of the Florida State University College of
Law.

About Orthofix:

Orthofix International N.V. is a diversified, global medical device company
focused on developing and delivering innovative repair and regenerative
solutions to the spine and orthopedic markets. Orthofix’s products are widely
distributed around the world to surgeons and patients via Orthofix’s sales
representatives and its subsidiaries, and via collaborations with other
leading orthopedic product companies. In addition, Orthofix is collaborating
on R&D activities with leading research and clinical organizations such as the
Musculoskeletal Transplant Foundation, the Orthopedic Research and Education
Foundation, and Texas Scottish Rite Hospital for Children. For more
information about Orthofix, please visit www.orthofix.com.

Contact:

Orthofix International N.V.
Mark Quick, 214-937-2924
Director of Investor Relations and Business Development
markquick@orthofix.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement